Analyst Price Target is $5.00
▲ +17.92% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Palisade Bio in the last 3 months. The average price target is $5.00, with a high forecast of $5.00 and a low forecast of $5.00. The average price target represents a 17.92% upside from the last price of $4.24.
Current Consensus is
The current consensus among 2 contributing investment analysts is to buy stock in Palisade Bio. This rating has held steady since January 2022, when it changed from a Hold consensus rating.
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.